191results about "Inactivation/attenuation" patented technology

The application discloses an isolation method of bovine epidemic fever virus and the bovine epidemic fever virus obtained by the method and application of the bovine epidemic fever virus, and belongs to the technical field of bovine epidemic fever virus isolation. The application aims to provide an efficient and rapid method for isolating bovine epidemic fever virus. The application provides the isolation method of the bovine epidemic fever virus, wherein the anticoagulated blood sample of a bovine is inoculated on KC cells for culture, the virus is harvested, the BHK-21 cells are inoculated to grow into a monolayer, and the first generation of passage cells with cytopathic effect is obtained by passage. The virus strain can also be used for screening, preparation and detection of bovine epidemic fever virus antibodies, and for preparation of an animal model infected by the bovine epidemic fever virus.

The invention relates to a genome large fragment deleted duck adenovirus B2 strain and application thereof, the duck adenovirus B2 strain is duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19, and is preserved in China Center for Type Culture Collection on September 26, 2025, and the preservation number is CCTCC NO: V202568. Compared with the duck adenovirus B2 strain BGMH, the duck adenovirus B2 strain has a deletion region between ORF20 and ORF53 genes, and the duck adenovirus B2 strain is deleted by 7422 bp. According to the invention, the duck adenovirus B2 strain with the genome deleted in large fragment is found for the first time, and the deletion region of the virus is a good site for inserting an exogenous gene, so that the duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19 can be used as a good virus vector to construct a recombinant virus, and the constructed recombinant virus can be stably inherited; the method can be applied to waterfowl novel recombinant virus vector vaccine research and development, waterfowl basic scientific research, gene virus vector delivery and the like, and has wide application prospect and value.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The invention belongs to the field of drug antivirus, and particularly discloses broad-spectrum antiviral application of punicalagin, the punicalagin has a structure shown in a formula 1, is good in stability and low in biological toxic and side effects, and can be used for developing novel broad-spectrum antiviral drugs.

The present invention provides materials and methods for viral engineering, including materials and methods for producing vectors and viral particles useful, for example, for gene therapy.

The high pathogenicity of the rift valley fever virus limits the research on the pathogenic mechanism and prevention, control and treatment products of the rift valley fever virus, the offspring replication-deficient virus particles are successfully saved through a reverse genetic manipulation technology, and the virus particles do not have the capacity of multiple rounds of infection on common cells; stable replication and passage can only be realized in a cell line for providing exogenous envelope glycoprotein; in addition, the virus particle carries an exogenous indication protein and can indicate cell infection. The Rift Valley fever virus-like particle provided by the invention can be used as a Rift Valley fever biosafety secondary laboratory research platform, the establishment of the virus particle greatly simplifies tedious procedures in the Rift Valley fever virus research process, and paves a way for screening of Rift Valley fever virus neutralizing antibodies, research and development of candidate vaccines and research of pathogenic mechanisms of the Rift Valley fever viruses.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

A cassette for the delivery of one or more mRNA is provided, the cassette comprising a 5' UTR, a Nodamura replicon, a ribosomal skipping polynucleotide, the one or more mRNA, a plant virus assembly origin polynucleotide ("OAS"), and a 3' UTR. In one aspect, the cassette further comprises a 5'mRNA cap. In a yet further aspect, the cassette does not comprise a poly A tail.

The invention provides a cell strain for producing engineered viroid particles, a method thereof and the engineered viroid particles, the cell strain is named as SZCV-Con28 and preserved in Guangdong Microbial Culture Collection Center on October 15, 2025, the preservation number is GDMCC No: 67101, and the preservation number is GDMCC No: 67101. A plurality of corresponding cell factories for producing the engineered viroid particles are established by cell lines obtained by introducing different target gRNA elements into the cell strain, so that the corresponding engineered viroid particles can be continuously produced in batches. According to the invention, large-scale preparation can be realized through cell expanding culture, the capacity limitation is overcome, the production process flow is simplified, and the consumption of production raw materials is reduced.

The present invention provides for modified Flavivirus such as a modified dengue virus type 1, 2, 3, 4, a combination of these, or a tetravalent combination of these. The modification according to various aspects of the invention results in reduced viral protein expression compared to a parent virus, wherein the reduction in expression is the result of recoding one or more regions of the virus. For example, the prM, or envelope (E) region can be recoded. In various embodiments one or more regions are recoded by reducing the codon pair bias or codon usage bias of the protein-encoding sequence. These modified Flaviviruses are used as vaccine compositions to provide a protective immune response.

Provided is a method for deactivating or removing viruses in a protein solution, the method including a step in which radiation treatment and virus removal membrane treatment or SD treatment are integrated and the conditions of these treatments are optimized to be mutually complementary. More specifically, the method includes: (a) a step in which a protein solution is treated by being irradiated with radiation so that the removal coefficient (LRV) for viruses with a virus particle diameter of less than 33 nm in the protein solution is at least 1.00; and (b1) a step in which viruses are removed from the treated protein solution by a virus removal membrane with an LRV of at least 4.00 for bacteriophage PP7, or (b2) a step in which the treated protein solution is brought into contact with a liquid mixture (SD liquid mixture) of an organic solvent and a surfactant and viruses are deactivated by organic solvent / surfactant treatment (SD treatment) so that the LRV for envelope viruses in the protein solution is at least 2.00. Also provided is a method for manufacturing a protein solution in / from which viruses have been deactivated / removed, the method including the abovementioned steps.

The disclosure provides for recombinantly modified Zika-based vectors that can be used in gene therapy applications.

It provides a vaccine platform that can be tailored to target any tumor type and appropriately stimulates the expansion of specific anti-tumor immune cells. [Solution] Provided are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to a biotinylated component (e.g., a tumor cell, a tumor antigen, a virus, or a viral antigen). The self-assembling pharmaceutical compositions can further comprise an immunotherapy (e.g., an anti-PD-1 antibody). Also provided are methods of using these pharmaceutical compositions for preventing and / or treating cancer or inducing an immune response. Also provided are methods of using the self-assembling pharmaceutical compositions in combination with immunotherapy (e.g., an anti-PD-1 antibody).

The invention relates to an immune system humanized mouse biological system for preparing a fully humanized monoclonal antibody and a method for preparing the fully humanized monoclonal antibody. The method comprises the following steps: using a constructed immune system humanized mouse and a VLP chimeric antigen; the HSC immune system humanized mouse is an immunodeficient mouse transplanted with human immune cells, the human immune cells are reconstructed, and antigen-specific B cells and fully humanized antibodies can be generated in the immune system humanized mouse by using a VLP chimeric antigen without firstly activating DC and antigen-specific T cells. In addition, by coupling a VLP antigen and a target antigen, a specific B cell and a fully human antibody of any target can be generated.

Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

The application discloses a preparation method of a tetravalent influenza virus split vaccine and belongs to the technical field of vaccines. The preparation method of the tetravalent influenza virus split vaccine comprises the following steps: pre-incubation of a chicken embryo, pre-embryo inspection, virus inoculation and culture, post-embryo inspection, cold embryo, virus harvesting, ultrafiltration clarification, zone centrifugation, desugaring, chromatography, virus splitting, virus inactivation, ultrafiltration liquid replacement, sterilization filtration and preparation of a tetravalent influenza virus split vaccine product. Compared with the prior art, the technical means adopted in the application effectively reduces the content of free formaldehyde and improves the antibody level of the vaccine.

The invention discloses a porcine epidemic diarrhea virus G2c genotype strain as well as a separation method and application thereof. Aiming at the current epidemic PEDV variant strain, the genetic variation rule of the epidemic strain is clarified by carrying out virus separation, identification and pathogenicity analysis, and the method has important significance on epidemiology, vaccine development and the like of the PEDV. Specifically, an applicant successfully separates a PEDV strain capable of realizing stable passage propagation in Vero-CCL81 cells from intestinal contents of diarrhea piglets collected from a pig farm of Jiangpermanent Province in Hunan, the PEDV strain is identified and determined as a porcine epidemic diarrhea virus G2c subtype, the PEDV strain is named PEDV CH / HNJY / 2025, the PEDV strain is preserved in China General Microbiological Culture Collection Center on December 11, 2025, and the preservation number of the PEDV strain is CGMCC NO. The preservation number is CGMCC (China General Microbiological Culture Collection Center)

The present disclosure relates to the field of biotechnology, in particular to a method for virus production. The present disclosure improves the culture method to improve the virus titer.

The invention belongs to the field of biology, and particularly relates to construction of a recombinant Seneca virus strain with Seneca virus 2B protein translation block site mutation. The 26th lysine (K) of the 2B protein is found to be a key site for inhibiting the translation of the host protein for the first time, and after the 26th K of the 2B protein is mutated into the alanine (A), the translation retardation phenomenon of the host protein is obviously weakened; secondly, the 26th K of the 2B protein is mutated into A to construct infectious clone, and the recombinant Seneca virus strain rSVA-2B K26A with 2B protein translation retardation site mutation is successfully rescued and obtained, compared with wild type SVA, after the rSVA-2B K26A infects host cells, the translation retardation phenomenon of the host cells is weakened, the expression level of host antiviral inflammatory cytokines is enhanced, and the expression level of the recombinant Seneca virus strain rSVA-2B K26A is improved. The Seneca virus vaccine strain can be used as a potential vaccine candidate strain, and a foundation is laid for developing a novel prevention and control strategy aiming at the Seneca virus.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The invention relates to recombinant polynucleotides encoding at least a recombinant polynucleotide expressing at least a first fusion polypeptide that comprises MHC class I T-cell epitopes suitable to elicit a T cell immune response in a host in need thereof, wherein the MHC class I T-cell epitopes originate from a plurality of antigens wherein the antigens comprise at least non-structural antigens and are from at least one flavivirus selected from the group of 10 Dengue virus (DENV), ZIKA virus (ZIKV) and Yellow Fever virus (YFV). The invention also relates to the polypeptides comprising polyepitopes of said antigens encoded by the recombinant polynucleotides.

A dendritic cell-targeted virus-like particle DVLP, and preparation method and application thereof. The virus-like particle DVLP is composed of a virus-like particle (VLP) encapsulated by an optimized Sindbis virus glycoprotein whose sequence is shown in SEQ ID NO.1. The preparation includes the following steps: optimizing the amino acid sequence of the envelope protein of wild-type Sindbis virus to obtain the SV-G gene sequence; constructing an expression vector of the SV-G gene, namely pCMV-SV-G; co-transfecting HEK293T cells with plasmids including pCMV-SV-G, pRSV-REV, an antigen expression vector, pMDlg / PRRE-D64V, and pMS2S-PH-gagpol-D64V, followed by transfection and purification. The virus-like particle DVLP has extremely high DC targeting ability and protein stability. After injection, the mRNA carried by the virus-like particle DVLP is mainly concentrated at the injection site and in lymph nodes, with a low risk of spreading to non-target organs such as the spleen, liver, and kidneys. Moreover, it can generate high-titer neutralizing antibodies to resist viral infection and protect the host, thereby providing a platform for the development of tumor vaccines.

A method for producing an inactivated influenza vaccine by an egg culture method according to the present disclosure includes a pathogen inactivation step for inactivating pathogens mixed in eggs, wherein the pathogens are other than influenza viruses.

The invention belongs to the technical field of veterinary vaccines, and particularly relates to an orf virus ORF114 or ORF117 gene deleted strain as well as a preparation method and application thereof. The orf virus ORF114 gene deleted strain is obtained by deleting ORF114 on the basis of an orf virus wild strain, and the orf virus ORF117 gene deleted strain is obtained by deleting ORF117 on the basis of the orf virus wild strain. According to the preparation method, on the basis of an ORFV-CF15 strain (ORFV 2015 strain), ORF114 and ORF117 genes of the ORFV-CF15 strain are deleted by using a gene recombination combined Cre-LoxP system, and two orf gene deleted strains are constructed and screened, and the orf virus ORF114 or ORF117 gene deleted strains have the characteristics of low toxicity, good proliferation and enhancement of Th1 type immune response, and can be used as orf gene engineering vaccine candidate strains.

This disclosure provides an attenuated suid herpesvirus 1 (a Pseudorabies virus) wherein the TK, gl and gE genes thereof are modified relative to a parent field strain, such that the resultant virus is safe and effective for use as a live vaccine that protects swine animals from challenge with a virulent Pseudorabies virus.

To provide recombinant biologically contained filovirus and methods for producing and using these viruses.SOLUTION: Provided herein is a vaccine comprising an effective amount of a recombinant filovirus and one or more adjuvants, where the genome of the recombinant filovirus contains a deletion of one or more nucleotides in a polynucleotide sequence for a viral protein corresponding to Ebola virus VP30, and where the deletion is effective to prevent expression of a functional viral protein corresponding to Ebola virus VP30 upon infection of a cell with the recombinant filovirus.SELECTED DRAWING: None

The present invention relates to a chimeric influenza virus hemagglutinin (HA) polypeptide comprising one or more stem domain sequences fused to one or more globular head domain sequences, each of the one or more stem domain sequences having at least 60% homology to a stem domain consensus sequence of an H1 subtype HA (H1 HA) and / or an H5 subtype HA (H5 HA), each of the one or more globular head domain sequences having at least 60% homology to a globular head domain consensus sequence of an H1 subtype HA (H1 HA) or an H5 subtype HA (H5 HA).

Embodiments of the present disclosure relate to systems and methods for adjusting the pH in a mixture containing a polypeptide. The pH can be adjusted for a suitable purpose, such as to inactivate viruses in the mixture. The method can include eluting the mixture (e.g., eluate) from a chromatography column, the mixture having a pH greater than 3.9, e.g., less than 8.5. The method can further include one or more of measuring the protein concentration of the mixture and measuring the pH of the mixture. The amount of acid required to lower the pH of the mixture to a target pH can then be calculated based on the protein concentration of the mixture, the pH of the mixture, or both. After calculating the amount of acid to be added, a portion of the acid can be added to the mixture, where the portion of the acid is sufficient to achieve the target pH.

The present invention relates to an influenza virus production method using a disposable culture process system and a rapid confirmation test for influenza virus antigen purification conditions. According to the present invention, the conditions for obtaining (purifying) influenza surface antigens can be confirmed quickly and reliably using a unique method of the present invention without using radial immunodiffusion, which is currently used as a standard test method in influenza vaccine production. This significantly shortens the production period for influenza surface antigen subunit vaccines and enables rapid response to vaccine development / production even in situations where a new influenza virus is rapidly spreading. Furthermore, according to the influenza virus production method of the present invention, the use of a continuous low-speed centrifuge using disposable bags allows culture medium exchange to be carried out in a closed system, significantly reducing the possibility of contamination during the virus production process.